Establishing New Paradigms
Signum Biosciences, Inc.® is a biopharmaceutical company focused on the discovery and development of innovative products to address major consumer and medical needs. Signum develops compounds and botanical extracts that are mimetics of natural lipid ligands crucial to cellular regulation and signaling.
We create skincare technologies with complete transparency. From our laboratory to your hands, we ensure each product is formulated with only the best ingredients with the goal of attaining and maintaining healthy skin.
Corporate Partnerships
Signum Partners
Clean + Simple
The Future of Skincare is Biotech
Discovering Novel Ingredients
Signum Biosciences has been behind the scenes over the last 20 years developing a library of novel ingredients to be utilized in a number of different ways. Over that time we developed new technologies to push our innovation for cosmetic ingredients that eventually led to the Epicutis® product line.
Developing Innovative Formulations
At Signum we always believed skincare could be pushed beyond beauty. By developing new technologies designed to compliment our skin's natural repair mechanism we can create more minimal formulations around powerful actives to provide truly clean products with medical grade concentrations.
Creating Products For Health
Our biotech background means we have an R&D team focused on developing new ingredients and formulations to continue to improve how we care for our skin. The ingredients we have on market today required years of development before arriving to you in a final formulation. Ingredients we are developing now won't be formulated for years as we ensure safety and efficacy across the entire list of ingredients.
Our History
1991
Discovery of Novel Signal Transduction Modulators (STMs)
Dr. Jeffry Stock discovered the power of a specific class of small molecules in his lab at Princeton where he modified S-farnesylcysteine into an active signal transduction molecule. The modifications made to this compound serves as the initial building blocks of our STM technology platform.
2003
Signum Founded
Dr. Stock and his son Maxwell Stock founded Signum Biosciences Inc.®, a biotechnology company spun out of Princeton University, whose focus is to develop novel ingredients for both the cosmetic and pharmaceutical space.
2008
TSC is Discovered
By continuing to modify small molecules in order to yield skin benefitting effects, TSC was created. Its ability to repair skin, lower inflammation and many other skin health promoting properties makes it a unique ingredient without comparison
2016
Masanori Tamura Joins Our Team
Signum’s corporate partner Rohto Pharmaceutical’s top formulator Masanori Tamura is the developer of Japan’s #1 moisturizer line Hada Labo. Tamura’s high-quality formulation efforts at Rohto attracted to the Signum Team’s attention while he was working in the US. After collaborating, Tamura joined the Signum team as our head formulator and director of Product Development.
2019
Hyvia® is Discovered
Our development of botanical extracts began as an interest in the foods we know to be therapeutic. By studying foods that humans already crave and consume we can make assumptions on why these foods are sought after. Chia seeds are exceptionally powerful and when put through our patented extraction process, yields a novel, proprietary topical oil that improves skin hydration and barrier function unlike any other on the market.
2020
Epicutis® is Created
After 20 years of dermatology focused R&D, Epicutis® is launched using unique, patented ingredients in simple formulations. We have created two products to help maintain skin health rather than trying to address the surface level symptoms of our skin.